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Abstract: Masked mycotoxins are plant metabolites of mycotoxins which co-contaminate common
cereal crops. Since their discovery, the question has arisen if they contribute to toxicity either directly
or indirectly through the release of the parent mycotoxins. Research in this field is rapidly emerging
and the aim of this review is to summarize the latest knowledge on the fate of masked mycotoxins
upon ingestion. Fusarium mycotoxins are the most prevalent masked mycotoxins and evidence is
mounting that DON3Glc and possibly other masked trichothecenes are stable in conditions prevailing
in the upper gut and are not absorbed intact. DON3Glc is also not toxic per se, but is hydrolyzed
by colonic microbes and further metabolized to DOM-1 in some individuals. Masked zearalenone
is rather more bio-reactive with some evidence on gastric and small intestinal hydrolysis as well as
hydrolysis by intestinal epithelium and components of blood. Microbial hydrolysis of ZEN14Glc is
almost instantaneous and further metabolism also occurs. Identification of zearalenone metabolites
and their fate in the colon are still missing as is further clarification on whether or not masked
zearalenone is hydrolyzed by mammalian cells. New masked mycotoxins continuously emerge and
it is crucial that we gain detailed understanding of their individual metabolic fate in the body before
we can assess synergistic effects and extrapolate the additive risk of all mycotoxins present in food.
Keywords: masked mycotoxins; deoxynivalenol; trichothecenes; zearalenone; absorption; hydrolysis;
intestine
1. Introduction
Mold infestation is an intractable problem in agricultural production affecting especially cereal
crops, nuts, and fruits either during plant growth or post-harvest. The fungal genera Aspergillus,
Pencillium, and Fusarium are most critical with regards to mycotoxin production. Mycotoxins are
secondary fungal metabolites which are highly toxic and their stability and persistence in the food
network are of major concern. The most important groups of mycotoxins include aflatoxins and
Fusarium mycotoxins [1]. Aflatoxins are class 1 human carcinogens with a global prevalence of 18%
in a survey of over 18,000 samples [2], but are not subject to plant metabolism and are therefore
not further discussed in this review. Among the Fusarium mycotoxins, the three major groups of
toxins are trichothecenes, zearalenone compounds, and fumonisins. The most common trichothecene,
deoxynivalenol, was found in 73% of tested samples whereas zearalenone occurred in 56% of all
samples globally [2]. Trichothecenes have a sesquiterpenoid basic structure with variable side chains
and an epoxide group which is linked to toxicity (Figure 1). While type A trichothecenes, namely
T2-toxin, HT2-toxin, and diacetoxyscirpenol (T2, HT2, DAS), are more potent toxins (tolerable daily
intake TDI for T2 + HT2 is 0.1 µg/kg body weight [3]), it is the type B trichothecenes, especially
deoxynivalenol (DON, TDI 1 µg/kg body weight [4]) and nivalenol (NIV), that are most commonly
detected in cereals [5]. Trichothecenes compromise small intestinal nutrient absorption and epithelial
barrier function and are immunotoxic [6–8]. Zearalenone (ZEN) and its hydroxylated derivatives
Toxins 2017, 9, 85; doi:10.3390/toxins9030085 www.mdpi.com/journal/toxins
Toxins 2017, 9, 85 2 of 10
α- and β-zearalenol (α-ZEL, β-ZEL) are lactone derivatives of phenolic resorcyclic acid which cause
strong estrogenic effects and reproductive toxicity (TDI 0.25 µg/kg body weight) [1,5]. The third group
of Fusarium mycotoxins are fumonisins, which are carcinogenic mycotoxins mainly found in corn
products [9], but they are not further discussed here as to date no plant-derived masked forms have
been described.
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In addition to the ell characterized fungal ycotoxins, plant-derived ycotoxin etabolites
have e erged as i portant co-conta inants in cereals [10]. These plant-derived, covalently bound
ycotoxin conjugates are also ter ed asked ycotoxins. Fusariu ycotoxins (especially ,
ZE , T2, T2, and IV) are the ost pro inent targets for plant etabolis utilizing phase II
conjugation reactions with small molecules such as monosaccharides, glutathione, or sulfates [11].
The most commonly detected masked mycotoxin conjugates are β-linked glucose-conjugates of
trichothecenes ( 3 lc, NIV3Glc, HT2Glc) and zearalenone (ZEN14Glc) [11,12] whereas both
α- and β-glucoside have been reported for T2-toxin [13]. Masked mycotoxins have been detected
in various cereals and cereal based foods. DON3Glc is found in wheat, maize, oats, and barley
at relative proportions of 20%–70% of free DON [10]. NIV3Glc has been reported to occur in
wheat at 12%–27% of NIV [14] and T2Glc and HT2Glc have been found in wheat and oats [15].
ZEN14Glc as well as α- and β-ZEL14Glc have been reported in breads and breakfast cereals at relative
proportions of 20%–100% of free ZEN [16] and ZEN16Glc has recently been identified as a novel
masked ZEN metabolite [17]. In addition to these single-sugar conjugates, di-, tri-, and tetra-glucosides
as well as mixed disaccharides and malonyl-glucosides have been described for DON, T2, HT2, and
ZEN [18,19]. Glutathione-conjugates of DON have been identified in barley [20], wheat, and oats [21].
Sulfo-conjugates have been described for ZEN (ZEN14S) in naturally contaminated animal feed [22]
and for DON (DON3S, DON15S) in artificially contaminated wheat [23,24]. Despite this growing list
of masked mycotoxins, the literature assessing their fate in the gut and predicting their contribution to
toxicity is rather limited. Mainly hampered by the li ited availability of purified compounds, most
work has been performed on DON3Glc and ZEN14Glc with some studies investigating other masked
mycotoxins (summarized in Table 1). No work has been performed to date on intestinal hydrolysis,
absorption, or toxicity of more complex mycotoxin-oligosaccharide conjugates.
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Table 1. Summary of published studies investigating digestion, absorption and toxicity of masked mycotoxins.
Mycotoxin Study Design Stomach Small Intestine Large Intestine Absorption Toxicity
DON3Glc In vitro Stable [25–28] Stable [25–28] Hydrolysed [25,26,28,29] <1% [27,28] <DON [30,31]
In vivo Stable [32] Stable [32] Hydrolysed (indirect evidence) [32–35] <DON [32–36] <DON [37,38]
DON3S In vitro ? ? ? ? <DON (translation assay) [23,24]but proliferative (HT-29 cells) [24]
DON-GSH In vitro ? ? ? ? <DON (translation assay) [39]
T2αGlc In vitro Stable [13,28] Stable [13,28] Hydrolysed [13,28] 0% [28] ?
T2βGlc In vitro Stable [13] Stable [13] Hydrolysed [13] ? ?
In vivo ? ? ? ? ?
HT2Glc In vitro ? ? Hydrolysed [40] ? ?
In vivo ? ? ? ? ?
NIV3Glc In vitro Stable [28] Stable [28] Hydrolysed [28,40] 0% [28] ?
In vivo ? ? ? ? ?
ZEN14Glc In vitro Stable [26,28] Stable [26,28] Hydrolysed and metabolised [26,28] <1% [31], 2.5% [41]>20% Hydrolysis [41] Non-cytotoxic (Caco-2, MCF-7 cells) [41,42]
In vivo 18% release [32] Not recovered [32] Not recovered [32] ? ?
ZEN16Glc In vitro ? ? ? <1% [41] Non-cytotoxic (Caco-2 cells) [41]
In vivo ? ? ? ? ?
ZEN14S In vitro Stable [26] Stable [26] Hydrolysed and metabolised [26] ? <ZEN [43]
In vivo ? ? ? ? 40% < ZEN [44]
αZEL14Glc In vitro Stable [28] Stable [28] Stable [28] <1% [28] <ZEN [45]
In vivo ? ? ? ? ?
βZEL14Glc In vitro Stable [28] Stable [28] Stable [28] 0% [28] ?
In vivo ? ? ? ? ?
?: No studies published.
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3. Toxicity of Masked Mycotoxins
Masked mycotoxins have long been thought to have limited bioavailability in the gut due to their
covalent binding, and hence do not contribute to toxicity. In silico analysis predicted that DON3Glc
cannot sterically bind to the ribosomal 60S subunit A-site pocket, the target for DON-induced ribosomal
toxicity, which was confirmed in vitro as a lack of downstream activation of MAPK in Caco-2 cells [30].
As a result, DON3Glc (0–10 µM) was found non-toxic to Caco-2 cells as it did not decrease cell viability
or disrupt intestinal barrier integrity [30] and was significantly less cytotoxic than free DON and
acetylated DON when using flow cytometry to determine cell viability, apoptosis, and necrosis in
IPEC-J2 porcine intestinal cells [31]. DON3Glc is also less immunotoxic than free DON [30,37]. Ex vivo
DON3Glc did not up-regulate pro-inflammatory cytokine gene expression or induce functional and
histological changes in porcine intestinal tissue explants [30]. In vivo DON3Glc was also shown to be
largely incapable of eliciting pro-inflammatory cytokine and chemokine mRNA responses observed
by DON in mice 2 and 6 h after oral exposure to 2.5 mg/kg body weight [37]. At similar dose
levels (2.5–10 mg/kg body weight), DON3Glc was also found to be less potent at stimulating plasma
elevation of gut satiety peptides and anorectic responses in mice and was markedly less potent at
inducing emesis in minks compared to parent DON [38]. Overall, toxicity studies in various models
focusing on different modes of toxicity all agree that the toxic potency of DON3Glc is much lower
compared to free DON.
Toxicity studies of other masked mycotoxins are scarce. MethylthioDON, a product of the
glutathione pathway in plants, was found to be 11-fold less toxic than DON in an in vitro translation
assay testing the inhibition of protein biosynthesis [39]. DON3S was found to be non-toxic in the same
in vitro translation assay [23,24], although a proliferative effect was reported in HT-29 colon cancer
cells in vitro, which will need further investigation [24].
ZEN14Glc has been tested in vitro and found to be non-cytotoxic to MCF-7 human breast cancer
cells (1 µM, 6 h) and Caco-2 cells (20 and 40 µM, 6 h) [41,42], and to exhibit reduced estrogen receptor
binding capacity compared to ZEN [45]. ZEN16Glc is also non-cytotoxic in Caco-2 cells [41]. ZEN14S
is also non-estrogenic in MCF-7 cells [43] and 40% less potent than ZEN in a rat uterus enlargement
bioassay in vivo [44].
4. Digestion and Absorption Masked Mycotoxins in the Upper Gastro-Intestinal (GI) Tract
4.1. In Vitro Digestion
Several in vitro studies have so far confirmed that DON3Glc is resistant to digestive juices of
the upper GI tract (saliva, stomach, pancreas, bile) without any significant release of DON [25–28].
No such studies have been performed with DON3S or DON-GSH. Similarly, other important masked
trichothecenes (T2αGlc, T2βGlc, HT2Glc, and NIV3Glc [13,28]) and masked zearalenone compounds
(ZEN14Glc, ZEN14S, αZEL14Glc, βZEL14Glc [26,28]) have been shown in vitro to be unaffected by
conditions prevailing in the upper GI tract. Masked trichothecenes (DON3Glc, NIV3Glc, T2αGlc at
2–2.3 nmol/mL) have also been shown not to be transported across intestinal epithelial monolayers
(Caco-2 or Caco-2/TC7) [27,28] while their free parent compounds were transferred to various degrees
(38% of DON, 6% of NIV, 42% of T2/HT2 transported after 24 h).
Results for masked ZEN14Glc are less in agreement. Our recent study has shown that neither
ZEN14Glc nor α- and β-ZEL14Glc were transported across the intestinal epithelial monolayers with
91%–93% of a 2 µM dose being recovered from the apical cell culture medium without any significant
release of free ZEN after 24 h of exposure [28]. In contrast to this, ZEN14Glc has been shown to be
hydrolyzed by Caco-2 cells with 20% of a 40 µM dose of apical ZEN14Glc being released as apical ZEN
after 4 h of incubation, but no hydrolysis of ZEN16Glc was reported [41]. Whether this discrepancy
stems from differences in dosing levels, Caco-2 cell clones, and/or culture conditions (e.g., DMEM
versus RPMI culture medium) remains to be elucidated in future studies. Another in vitro study
showed the hydrolysis of ZEN14Glc to ZEN and further metabolism by the human breast cancer cell
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line MCF-7, but the authors used complete culture medium supplemented with fetal bovine serum and
suggest that serum components rather than cells may have hydrolyzed the masked compound [42].
Subsequently the hydrolysis of ZEN14Glc has been confirmed in bovine whole blood, plasma, and
serum [46]. More work is required to clarify the issue of potential uptake and hydrolysis of ZEN14Glc
by mammalian cells.
4.2. In Vivo Digestion and Absorption
The first report on masked mycotoxins in vivo dates back to 1990 when Gareis et al. [47] observed
in one pig that ZEN14Glc (600 µg/d over 14 days) was decomposed during digestion and that ZEN and
ZEL were detectable urinary and fecal metabolites. Authors report complete hydrolysis of ZEN14Glc
but no associated clinical signs of estrogenic activity. Over two decades later the next in vivo study
was performed as short term dosing (55 min) in two rats [32]. ZEN14Glc was rather unstable in the
stomach (only 35% and 46% of dose recovered as ZEN14Glc) and rapidly hydrolyzed to free ZEN
(16% and 19%). Only minimal amounts of intact ZEN14Glc were detectable in the intestine (0.5% in
the small intestine, 2.5% in the colon). From these two studies, it appears that ZEN14Glc is rapidly
hydrolyzed in vivo and therefore very likely to contribute to toxicity, but further work is needed to
fully understand toxicokinetics and species differences.
Amongst trichothecenes, most in vivo studies have been performed with DON3Glc comparing
its metabolism, absorption, and excretion to DON. In the rat study by Versilovskis [32], DON3Glc
(25 µg/d or approximately 90 µg/kg body weight) was mainly recovered intact in the stomach (37%
and 51% of the dose) whereas the release of free DON was negligible (2% in the stomach). In the small
and large intestine, only traces of DON3Glc (1%–3%) and no free DON were found. Another single
dose study in rats (2.0 and 3.1 mg/kg body weight of DON and DON3Glc, respectively) found fecal
excretion as the major route of toxin elimination after DON and DON3Glc dosing (approximately 65%
of an oral dose for both toxins over 48 h [33,34]). Sulfonate metabolites of DON and DOM-1 were
major fecal metabolites for rats dosed with DON and DON3Glc, whereas DON3Glc-sulfonate was only
found after dosing with DON3Glc. Fecal free DON plus DOM-1 comprised about 15% of the total dose
of both toxins. Urinary metabolites only comprised 10% of the dose for DON and 5% of the dose for
DON3Glc, suggesting low bioavailability of DON in rats, and even lower bioavailability of DON3Glc.
The fate of DON3Glc in the pig appears to be rather different. Following oral dosing of DON3Glc
(116 µg/kg body weight), urinary DON was the main excretion product after 24 h (21.6% of the dose)
followed by urinary DON-glucuronides (10.2%), DOM-1 (5.9%), and DON3Glc (2.6%), as well as fecal
DOM-1 (1.8%), adding up to a total recovery of 42.1% of the dose [35]. The recovery of an equimolar
dose of free DON was twice as high (84.8% as urinary DON and DON-glucuronides) in the same study.
Possible explanations for the low recovery of DON3Glc were the formation of DOM-1 glucuronides
(which were not detected in that study) and incomplete elimination of all metabolites within 24 h as
a result of the delayed large intestinal breakdown of DON3Glc. Another toxicokinetic study in pigs
comparing oral dosing of DON and DON3Glc (36 and 55.7 µg/kg body weight, respectively over
8 h) found that DON3Glc is absorbed (as DON) much more slowly than DON (time to maximum
plasma concentration is 225 min for DON3Glc versus 44 min for DON) and much less efficiently
(absorbed fraction 16.1% for DON3Glc versus 81.3% for DON). DON3Glc was not absorbed intact at
all (absolute oral bioavailability 0%). In broilers, neither mycotoxin is absorbed efficiently (5.6% and
3.8% oral bioavailability for DON and DON3Glc, respectively), possibly explaining this species’ low
susceptibility to DON [36]. In summary, oral bioavailability and absorption of DON3Glc in pigs is
significantly lower and slower compared to DON. Nevertheless, urinary excretion is the main route of
toxin elimination suggesting hydrolysis of DON3Glc in the lower gut and significant uptake of DON
metabolites from the colon. A more complete picture of all possible metabolites monitored over a
longer period (48–72 h) is still lacking. Other species (rat and broiler chicken) do not appear to absorb
DON3Glc or DON very efficiently, which may explain their lower susceptibility to DON compared
Toxins 2017, 9, 85 6 of 10
to pigs. However, when predicting human exposure, the pig is thought to be the best model, raising
concern about the fate of DON3Glc in the human large intestine.
As far as the other masked mycotoxins are concerned, there is very limited evidence on the
hydrolysis of ZEN14Glc in vivo and no evidence on any other masked compounds. This gap of knowledge
clearly needs to be addressed in future work.
5. Degradation of Masked Mycotoxins in the Lower GI Tract
The contribution of intestinal microbiota to the breakdown and metabolism of dietary compounds
and xenobiotics is being widely recognized, but microbiome activity is difficult to study and predict
in vivo. Hence microbial hydrolysis of masked mycotoxins has been studied in vitro using human
fecal microbiota or single isolates of human gut microbes. Several studies have demonstrated complete
microbial hydrolysis of DON3Glc after 24 h of incubation [25,26,28,29]. Kinetics of hydrolysis are
similar for DON3Glc and NIV3Glc, but slower for T2αGlc in mixed fecal incubations [28]. Microbial
hydrolysis rates of T2αGlc and T2βGlc were found to be similar, but T2βGlc was cleaved to T2 and HT2
while 30% of T2αGlc was converted to unknown metabolites, which could include HT2Glc, T2-triol, or
T2-tetrol [13]. The identity and toxicity of these metabolites remains to be elucidated. Kinetic studies
with purified recombinant glycosyl hydrolase (GH3) enzymes derived from Lactobacillus brevis and
Bifidobacterium adolescentis showed significantly slower kinetics for the hydrolysis of NIV3Glc compared
to DON3Glc, although assays were performed at 10-fold lower concentrations [40]. Regarding masked
ZEN compounds, ZEN14Glc, ZEN14S, as well as α- and β-ZEL14Glc are all very rapidly hydrolyzed
by mixed fecal microbiota with recovery of intact masked compounds dropping below 20%–40%
after 30 min of incubation [26,28]. Furthermore, the microbial metabolism of ZEN14Glc leads to
complete disappearance of known metabolites (ZEN14Glc, ZEN, α- and β-ZEL), suggesting further
transformation to yet unidentified metabolites.
The covalent binding of masked mycotoxins to sugar residues significantly limits their absorption
in the small intestine and acts as a delivery mechanism for masked mycotoxins to the colon. In the
colon, simple masked mycotoxins have been shown to be efficiently hydrolyzed and free mycotoxins
released. It is highly likely that di-, tri-, and tetra-saccharide masked mycotoxins can also be cleaved
by the gut microbiome, as the metabolic network of gut microbiota comprises a vast arsenal of
carbohydrate-active enzymes capable of degrading a multitude of polysaccharides and glycans [48].
It remains unknown how early that mycotoxin release will occur in the large intestine and how efficient
the colonic absorption may be.
In addition to releasing free parent mycotoxins, further microbial metabolism has also been
reported for DON [29]. DOM-1 can be used as a purely microbe-derived mycotoxin metabolite to
extrapolate colonic uptake. In pigs dosed with DON, no DOM-1 was detectable in feces or urine
whereas dosing with DON3Glc resulted in detectable levels of DOM-1 in feces and urine (2.1% and
5.9% of dose, respectively) [45]. DON3Glc exposure in pig therefore results in a urinary DOM-1 ratio of
18% of urinary DON (free + conjugated) whereas DON exposure results in 0% DOM-1. In humans, we
have observed urinary DOM-1 ratios at 1.3%–7.7% of urinary DON (free + conjugated) in individuals
harboring a microbiota capable of DOM-1 production [46]. These individuals will most likely have
been co-exposed to DON and DON3Glc through their habitual diet. Dietary DON would then be
mainly absorbed in the small intestine and excreted as urinary DON whereas dietary DON3Glc would
be delivered to the colon, hydrolyzed, and partially metabolized to DOM-1 by microbiota and would
thereafter be absorbed and excreted as urinary DON and DOM-1. However, conclusive evidence on
colonic absorption of microbial mycotoxin metabolites and their potential role in low-grade colonic
toxicity needs to be generated through future investigations. It will be crucial that future toxicokinetic
studies and risk assessments take into account the contributions of microbial release and metabolism of
mycotoxins and other xenobiotics, as well as their colonic absorption to gain a complete understanding
of the fate of these compounds in the body [46].
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6. Summary and Conclusions
The literature indicates that masked mycotoxins are significantly less toxic than their free parent
compounds, although only DON3Glc has been studied thoroughly. Masked mycotoxins are also stable
under conditions present in the upper GI tract and their intestinal absorption appears significantly
lower than the free mycotoxins. However, the difference between the two most studied masked
mycotoxins, DON3Glc and ZEN14Glc, is striking. DON3Glc is rather inert, withstands small intestinal
digestion, and is not absorbed into epithelial cells or systemic circulation, but is efficiently hydrolyzed
into free DON (and occasionally DOM-1) by gut microbiota. DON itself is also stable, circulating
through the body and being excreted mainly as glucuronidated DON via urine. ZEN14Glc on the
other hand appears much more biologically reactive with hydrolysis to free ZEN, hydroxylation to α-
and β-ZEL, and further metabolism to yet undetermined metabolites occurring in blood, cell culture
medium (when supplemented with fetal serum), and possibly epithelial cells. Upon contact with
gut microbiota, ZEN14Glc is hydrolyzed and metabolized almost instantaneously into yet unknown
metabolites. The fate of the resulting metabolites in terms of colonic absorption and toxicity remains to
be determined. It is also unknown how steriochemically different isomers (e.g., ZEN16Glc) or more
complex di- and trisaccharide masked compounds may be hydrolyzed by microbiota.
In conclusion, masked mycotoxins may not be viewed as a homogenous group of contaminants
but rather as a complex mixture of different plant metabolites of various classes of mycotoxins, and
their entirety has been termed as ‘maskedome’ [49]. It is crucial that we gain a detailed understanding
of the fate of each individual masked mycotoxin before we allow the generalization of results and
prediction of the metabolic fate of novel masked compounds.
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